Zimmer Biomet Holdings, Inc. (ZBH) 股票分析

公司概述

Zimmer Biomet Holdings, Inc. operates globally as a medical technology company, designing, manufacturing, and marketing orthopedic reconstructive products such as knee and hip implants, S.E.T. products covering sports medicine, biologics, foot and ankle, and urology devices. The firm functions within the Healthcare sector and the Medical Devices industry, positioning it as a provider of critical infrastructure for patient mobility and surgical intervention rather than a consumer-facing utility or financial service entity. The company's scale is quantified by a market capitalization of $18.20B, annual revenue of $8.23B, and a workforce of 17,000 employees. These valuation and revenue figures indicate that Zimmer Biomet is a significant, large-cap entity with substantial market penetration, suggesting established brand recognition and a diversified product portfolio capable of generating multi-billion dollar sales volumes.

财务健康

The company reported a Total Revenue (TTM) of $8.23B and Net Income (TTM) of $705.10M, while EBITDA reached $2.50B; the substantial gap between revenue and net income reveals a cost structure where operating expenses, including cost of goods sold, research and development, and administrative costs, consume approximately 91.4% of total revenue before interest and taxes are accounted for. Free Cash Flow stands at $1.35B, indicating strong financial flexibility that allows the firm to service its obligations, fund capital expenditures, or pursue strategic acquisitions without relying heavily on external equity financing. The Gross Margin is 69.7%, Operating Margin is 14.0%, and Profit Margin is 8.6%, where the high gross margin reflects the premium pricing power of specialized orthopedic devices, while the lower operating and profit margins highlight the significant overhead burdens inherent in a capital-intensive manufacturing and global logistics business. Total cash on hand is $620.90M against total debt of $7.87B, resulting in a Debt to Equity ratio of 61.97, which suggests a leveraged balance sheet where long-term obligations significantly outweigh liquid assets and shareholder equity. The Current Ratio is 1.98, indicating robust short-term liquidity where current assets are nearly double current liabilities, providing a comfortable buffer against immediate payment obligations. Return on Equity is 5.6% and Return on Assets is 3.9%, metrics that reveal moderate management effectiveness in generating returns relative to the capital invested and the total asset base utilized.

估值评估

The Trailing P/E Ratio (TTM) is 26.20 while the Forward P/E is 10.35, implying a sharp divergence where the market prices in significantly higher expected earnings growth for the future compared to the depressed current earnings. The Price to Book ratio is 1.43, indicating that the market values the company at 43% above its book value, reflecting a premium for intangible assets like intellectual property, brand equity, and the quality of its medical device portfolio. The Price to Sales ratio is 2.21 and the EV/EBITDA is 10.20, suggesting that the company is trading at a valuation multiple that is moderate relative to its sales but requires careful scrutiny given the earnings contraction. The 52-week High is $108.29 and the 52-week Low is $84.59, meaning the current stock price sits within this trading range, specifically reflecting a position that is volatile relative to its recent highs and lows. The Beta is 0.61, which signifies that the stock price volatility is less than 40% of the broader market's movements, offering a lower correlation to general market swings compared to the S&P 500.

Growth & Income

Revenue Growth (YoY) is 10.9% while Earnings Growth (YoY) is -40.8%, demonstrating that earnings are growing significantly slower than revenue due to the sharp decline in profitability. As a dividend payer, the company offers a Dividend Yield of 1.0% with a Payout Ratio of 27.0%, a low payout ratio that suggests the dividend is currently sustainable even with negative earnings growth, though it relies on cash flow generation rather than net income. The divergence between the 10.9% revenue expansion and the negative earnings growth highlights a structural challenge where top-line momentum has not yet translated to bottom-line profitability, likely due to the aforementioned margin compression or one-time charges affecting the Net Income calculation. The overall growth and income profile presents a scenario of top-line expansion coupled with significant earnings contraction, supported by a conservative dividend payout that prioritizes capital preservation over aggressive shareholder returns.